San Diego, CA, United States of America

Wendy Cordier

This inventor holds 2 USPTO granted patents. Top assignee: Centocor Ortho Biotech Inc.. Active years: 2012-2013.


Average Co-Inventor Count = 14.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2012-2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Wendy Cordier: Innovator in Antibody Engineering

Wendy Cordier is a prominent inventor based in San Diego, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of engineered antibodies. With a total of 2 patents, her work focuses on therapeutic applications that target specific proteins.

Latest Patents

Wendy's latest patents include the invention of engineered anti-IL-13 antibodies, which are immunospecific for the human interleukin-13 (IL-13) protein or its fragments. These patents detail methods of making and using these antibodies, highlighting their potential therapeutic indications. The innovative nature of her work addresses critical health issues related to IL-13, making her contributions invaluable to the medical community.

Career Highlights

Wendy Cordier is associated with Centocor Ortho Biotech Inc., where she has been instrumental in advancing research and development in antibody engineering. Her expertise in this area has positioned her as a key figure in the biotechnology sector.

Collaborations

Throughout her career, Wendy has collaborated with notable colleagues, including Ronald Swanson and Ellen Chi. These partnerships have fostered an environment of innovation and have contributed to the success of her projects.

Conclusion

Wendy Cordier's work in engineered antibodies exemplifies the impact of innovation in biotechnology. Her patents and collaborations reflect her commitment to advancing therapeutic solutions. Wendy continues to be a driving force in her field, paving the way for future advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…